The Miracle
Bean
[source: PHYTOCHEMICALS:
GUARDIANS OF OUR HEALTH,
General Conference Nutrition
Council, Andrews University
Department of Nutrition, Andrews
University, Michigan] Chinese
having a regular consumption of
soybeans and/or tofu have only
one-half as much cancer of the
stomach, colon, breast and lung
compared with those Chinese who
rarely consume soy or soy
products. Soybeans contain fairly
high levels of several compounds
with demonstrated anti-cancer
activity, including a high
content of isoflavonoids, such as
genistein. These isoflavonoids
have been shown to inhibit the
growth of both human breast and
prostate cancer cells. In
addition, regular use of soy
protein (soybeans, tofu, soy
nuts, soy beverage) can lower
blood cholesterol and
triglyceride levels by 10 to 15
percent, especially in persons
with elevated lipid levels.
Eating Soy
Bean to Fight Cancer
[source: Medicinal
Food News, Vol 2, 1998, Issue
5
For many of us the only time soy
got into our diet was when we
used salad dressing made from
soybean oil. More and more people
are eating soybeans as they learn
about the many benefits of this
legume. Soybeans are rich in
plant phytoestrogen hormones
called isoflavones. These
isoflavones are similar in
structure to the estrogens in the
human body and so adding soybeans
to the diet may be a way of
increasing estrogen levels.
That at least is the reasoning
behind the interest in soybeans
by women approaching menopause.
The observation that the Japanese
and Chinese have low incidences
of breast, colon and prostate
cancer has led researchers to
investigate other components of
soybean that may be beneficial to
health. In an article published
recently in the Journal of the
National Cancer Institute
laboratory work has pointed at a
compound called genistein as a
possible anti-cancer agent in
soybean. Genistein appears to
affect the metabolism of cancer
cells by weakening their defences
against anti-cancer drugs and
treatments such as chemotherapy
and radiation treatment. Cancer
cells have developed enzyme
systems to produce protective
proteins that allow the cancer to
resist treatment. Genistein
appears to be able to interfere
at the production of these
protective proteins, thereby
reducing the ability of cancer
cells to survive and grow. So
there may be more than one reason
why you would want to increase
the amount of soybean in your
diet. It is the protein part that
contains the genistein; adding
more soybean oil to your salad
won't help.
Nutritional information, books
and recipes for soybean can be
found at http://soyfoods.com
Soy Products,
Breast Cancer, and Other Diseases
The NBC show,
"Dateline" of June 9,
reported the overall benefits
of consumption of soy products.
One of the highlights of the
article was the connection of
increased soy consumption and
protective effects against breast
cancer. My work explains
these beneficial effects of soy
consumption. Soy increases
production of the hormone,
dehydroepiandrosterone (DHEA).
I suggest DHEA is necessary
for growth and development of all
tissues and adult tissues
require DHEA for proper
maintenance. A subordinate
hypothesis of this is that the
stability of cells depend upon
DHEA. This eventually
resulted in my explanation of cancer
as a result of reduced DHEA.
That is, reduced DHEA may trigger
oncogene (genes of cancer)
activation. DHEA begins to
decline after age 20-25, reaching
very low levels in old age. I
suggest this is why cancer
incidence increases with age.
Measurable levels of DHEA are
reduced in women with breast
cancer, and this reduction occurs
as early as nine years prior to
diagnosis (Geriatrics 1982; 37:
157). A number of studies
demonstrate that treatment
with DHEA provides a protective
effect against breast cancer.
That is, raising DHEA reduces the
incidence of breast cancer. One
citation that reports this also
found beneficial effects of DHEA
in other areas important to aging
women. "These data show that
DHEA exerts a stimulatory effect
on bone mass and an inhibitory
effect on serum triglycerides, as
well as a protective effect on
the development of mammary
carcinoma induced by DMBA in he
rat. Such data suggest that while
decreasing the risk of breast
cancer, DHEA replacement therapy
could also exert beneficial
effects on the bond and lipid
metabolism in women receiving
DHEA replacement therapy."
(Endocrinol. 1997; 138: 3387).
Therefore, increasing DHEA
reduces breast cancer incidence.
A connection of soy consumption,
reduced breast cancer, and
increased levels of DHEA sulfate
(the serum precursor of DHEA) was
reported in 1995. "There
is also evidence that soy
products may affect risk factors
for cancer, such as endogenous
hormone levels. Preliminary
data from our group indicate that
young Adventist women who are
vegetarians with high soy intake
and a lower risk of breast cancer
may have higher levels of an
adrenal androgen,
dehydroepiandrosterone
sulfate." (J. Nutr. 1995;
125(3 Suppl): 709S-712S). It was
suggested on "Dateline"
that the increase in breast
cancer in Japanese women, who
move to the U.S., may be a result
of reduced soy consumption in
this country.
A number of studies have reported
general benefits of DHEA
treatment in aging men and women.
"DHEA in appropriate
replacement doses appears to have
remedial effects with respect to
its ability to induce an anabolic
growth factor, increase muscle
strength and lean body mass,
activate immune function, and
enhance quality of life in aging
men and women, with no
significant adverse
effects." (Ann. N. Y. Acad.
Sci. 1995; 774: 128) The
"Dateline" article
included a discussion with an
investigator who suggested many
beneficial effects of soy
consumption in many diseases. I
suggest these, and the protective
effect of soy on breast cancer,
are the results of increases in
DHEA. It is the increase in DHEA
that may produce the real
beneficial effects.
Copyright © 1997 by James
Michael Howard.
Soy Products,
Ginseng May Lower Breast-Cancer
Risk
[Medical Tribune: Family
Physician Edition 38(20): 1997.
© 1997 Jobson Healthcare Group]
SAN ANTONIO--Tofu and other soy-based
foods--and possibly even the
herb ginseng--may help
women stave off breast cancer,
according to preliminary research
presented here last month at the
annual meeting of the American
Osteopathic Association.
In a laboratory study of human
breast-cancer cells, high amounts
of isoflavones--dietary
components found in soy-based
products--stunted the growth of
cancerous cells by as much as
30%, reported Donna Dixon
Shanies, Ph.D., an assistant
professor of biochemistry and
genetics at the New York College
of Osteopathic Medicine in Old
Westbury, N.Y.
In a second laboratory study, Dr.
Shanies found that traditional
Chinese herbal remedies including
ginseng and vitex berry extract
also inhibited the growth of
human breast-cancer cells.
Because they are loaded with
phytoestrogens, isoflavones may
help prevent breast cancer by
reducing levels of natural
estrogen in the body, she
explained. Or isoflavones may
have antioxidant properties that
inhibit tumor development. "Phytoestrogens
may in the future prove to be
promising agents used to reduce
the risk of breast cancer and
other hormone-dependent cancers,
such as prostate cancer,"
Dr. Shanies said.
Although there are no
recommendations concerning how
much soy individuals should
include in their diets, she said,
"it would be prudent for
women to try to eat more soy
products."
Dr. Shanies and colleagues tested
the effects of three major
isoflavones--biochanin A, daidzein
and genistein--on human
breast-cancer cells. They also
measured the effects of ginseng,
black cohosh root, dang gui root,
hops flower, vitex berry and shiu
chu ginseng root on breast-cancer
cell lines.
Calling the new research "a
promising first step,"
Richard J. Cenedella, Ph.D.,
chairman of the department of
biochemistry at the Kirksville
College of Osteopathic Medicine
in Kirksville, Mo., said the
findings add a new dimension to
what is understood about the link
between diet and breast cancer.
"We have always known that
there are beneficial effects of a
low-fat diet [on breast-cancer
risk], and concentrations of
trace plant hormones found in
certain foods may play a role in
the reduced risk," Dr.
Cenedella said. --D.M.
Phytoestrogens
of Soybeans: An Alternative
Approach to Traditional HRT?
Presented at "The Health
Impact of Soy Protein
Symposium"
UCLA Center for Human Nutrition,
January 20, 1998
by
Thomas B. Clarkson, D.V.M.
Professor of Comparative Medicine
at the Wake Forest University
School of Medicine
Traditional postmenopausal
hormone replacement therapy (HRT)
preserves bone density, reduces
the risk for coronary heart
disease and may sustain cognitive
function with aging. Despite
these health benefits compliance
is poor (about 10 percent of
women older than 55 years). Poor
compliance relates primarily to
fear of breast cancer and the
need for co-administration of
progestin to those with uteri. We
have focused on the phytoestrogens
(genistein and daidzein) from
soybeans as potential
alternatives to traditional HRT
- particularly because they may
be breast cancer protective and
are antiestrogens for the
endometrium thus obviating the
need for a progestin.
Cardioprotective Effects.
We have compared soy
phytoestrogens (SBEs) and
conjugated equine estrogens (CEE)
administered to surgically
postmenopausal monkeys to their
effects on plasma lipoproteins
concentrations. SBEs increased
HDL cholesterol and Apo A1 more
than CEE and LDL cholesterol was
decreased more by SBEs. CEE, but
not SBEs, resulted in
hypertriglyceridemia. Data on
atherosclerosis of postmenopausal
female monkeys is incomplete but
both soy phytoestrogens and CEE
inhibit the progression of
atherosclerosis. Soy
phytoestrogens, like estradiol,
enable coronary arteries to
dilate in response to
acetylcholine.
Breast and Endometrial
Effects. We have compared the
effects of SBEs and CEE on the
breast and uterus of
postmenopausal monkeys. SBEs are
not estrogen agonist for either
breast or endometrium. Moreover,
they are estrogen antagonist at
these sites, preventing the usual
proliferative changes induced by
estradiol.
Brain Effects. Soy
phytoestrogen's effect on brain
biomarkers of cognition (brain
derived-neurotrophic factor and
acetylcholine production) are
comparable to those of estradiol.
UCLA Center for Human
Nutrition
900 Veteran Avenue
Los Angeles, CA 90095-1742
Soy Protein
Isoflavone Effects on Breast
Tissue
Presented at "The Health
Impact of Soy Protein
Symposium"
UCLA Center for Human Nutrition,
January 20, 1998
by
Stephen Barnes, Ph.D.
Professor of Pharmacology &
Toxicology and Biochemistry &
Molecular Genetics in the School
of Medicine at the University of
Alabama at Birmingham
Isoflavones, so
abundant in soy, have been shown
to have biochemical and
biological effects in a variety
of in vitro and animal models.
These effects are not only based
on the estrogenic properties
of isoflavones, but also their
role as protein tyrosine kinase
inhibitors, regulators of gene
transcription, modulators of
membrane transporters, and as antioxidants.
Predicting the outcome of the
effects of isoflavone-rich diets,
such as those based on soy, on
chronic diseases (cancer and
heart disease) should not be
based on one of these mechanisms
alone. For instance, the prevention
of osteoporosis by
isoflavones (an estrogenic
effect) is in contrast with
epidemiological and laboratory
data which suggest soy and
isoflavones prevent cancer.
However, the recent discovery of
new estrogen receptor (ERP) which
selectively binds the isoflavone
genistein is providing new
rationales to explain the
estrogen paradox. ERP shows a
different tissue distribution
from the classical estrogen
receptor, being abundant in bone,
the brain, cardiovascular system,
genitourinary system, lungs and
prostate, but not in the breast.
This allows genistein to have
beneficial effects at these
targets without increasing the
risk of breast cancer. Thus the
isoflavones may be naturally
occurring forms of an important
new class of drugs called
selective estrogen receptor
modulators (SERMs), being
developed for the treatment of
the postmenopausat disease in
women.
UCLA Center for Human
Nutrition
900 Veteran Avenue
Los Angeles, CA 90095-1742
More Abstracts
Copyright 1998
Indiana Soybean Board
Cancer killer
A hormone in soya beans
starves tumour cells to death
[New Scientist 14 mar 98]
BIOCHEMISTS in the US have
worked out how a key ingredient
in soya beans thwarts cancer.
Thev have shown that genistein,
a plant oestrogen, plays a
pivotal role in suppressing
the growth of cancerous cells.
Asian diets high in soya have
been linked with low incidence of
cancers, particularly breast,
colon and prostate cancers. This
link has been reinforced by
evidence that when Asians migrate
to the US and abandon the
high-soya diet, their risk of
developing these cancers
increases. Amy Lee of the
University of Southern California
in Los Angeles has discovered
that genistein is a key factor in
this. It works by weakening
cancer cells' response to the
stresses that usually impel them
to grow faster. "When a
cancer cell is growing at full
blast, the cells soon run out of
oxygen and glucose that are
normally supplied in blood,"
savs Lee. To compensate, they
send out a chemical SOS which
triggers formation of new vessels
to nourish the tumour, a process
called angiogenesis.
In earlier experiments on tissue
cultures, Lee and others proved
that genistein can blunt the
response of cancer cells to
stress. Now, they know the exact
mechanism. She and her colleague
Yanhong Zhou have shown that
genistein blocks the action of a
transcription factor known as
CCAAT binding factor. This
protein normally binds to an
important genetic
"motif" in DNA and
triggers the stress genes.
Genistein adds phosphorus to the
binding factor, neutral- ising it
before the snvitch is tripped, so
the cancer cell starves, withers
and dies (journal of the National
Cancer Institute, vol 90, p 381).
"This is preliminary
evidence, but genis- tein really
stands out as the ingredient
that's most active in stopping
cancer growth and
angiogenesis," says Lee.
Crucially, the researchers found
that genistein has no effect on
normal, healthy cells which are
not dividing rapidly like cancer
cells. "It doesn't shut off
the normal synthesis of this
protein in healthy cells,"
says Lee. Andy Coghlan
|